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ABSTRACT
Bladder cancer is one of the leading cancer of the urinary tract. It is often 
diagnosed at advanced stage of the disease. To date, no specific and effective 
early detection biomarkers are available. Cancer development and progression are 
associated with the involvement of both epithelial-mesenchymal transition (EMT) and 
tumor microenvironment of which NGAL/MMP-9 complex represents the main player 
in bladder cancer. It is known that change in microRNAs (miRNAs) expression may 
result in gene modulation. Therefore, the identification of specific miRNAs associated 
with EMT pathway and NGAL/MMP-9 complex may be useful to detect the development 
of bladder cancer at early stages. 
On this ground, the expression levels of miRNAs in public available datasets 
of bladder cancer containing data of non-coding RNA profiling was evaluated. This 
analysis revealed a group of 16 miRNAs differentially expressed between bladder 
cancer patients and related healthy controls. By miRNA prediction tool (mirDIP), the 
relationship between the identified miRNAs and the EMT genes was established. Using 
the DIANA-mirPath (v.2) software, miRNAs, able to modulate the expression of NGAL 
and MMP-9 genes, were recognized.
The results of this study provide evidence that the downregulated hsa-miR-145-5p  
and hsa-miR-214-3p may modulate the expression of both EMT and NGAL/MMP-9 
pathways. Therefore, further validation analyses may confirm the usefulness of these 
selected miRNAs for predicting the development of bladder cancer at the early stage 
of the disease.
INTRODUCTION
Bladder cancer is one of the most common worldwide 
malignancies. In developed Countries, it is the ninth most 
frequent cancer and the fourteenth leading cause of death in 
cancer patient [1]. In urology, bladder cancer is the second 
most prevalent malignancy after the prostate cancer [2]. 
According to the GLOBOCAN 2012 Cancer Fact Sheets, in 
the most developed Countries Bladder cancer incidence is 
three times higher among men (6.1%) than among women 
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(2.0%). The corresponding mortality rates for men and 
women are 3.7% and 1.6%, respectively [3]. 
Several factors contribute to the development of 
bladder cancer, including tobacco smoking, as the major risk 
factor [4, 5]. Other risk factors are represented by obesity, 
hypertension, diabetes, and chronic exposure to aromatic 
amines and nitrosamines contained in paints and dyes [6–8]. 
In addition, the development of bladder cancer is promoted 
by unhealthy food habits and metabolic syndrome [9, 10].
Unfortunately, the percentage of recurrence for this 
cancer is very high and patients need to be frequently 
monitored. Although invasive and expansive, cystoscopy 
remains the most appropriate diagnostic technique 
used for the diagnosis and follow-up of bladder cancer. 
Another diagnostic method is the urinary cytology test, 
but this technique does not seem to have much sensitivity, 
especially in low-grade bladder cancer, although it is well 
tolerated by patients [11–13].
The discovery of new markers may be helpful for an 
early diagnosis and for classifying patients with high risk 
of cancer recurrence. A growing body of evidence suggests 
that microRNAs (miRNAs) can be used as markers with 
high specificity and sensitivity capable of identifying 
early cancer lesions through the study of the interactions 
between specific miRNAs with different pathways of 
tumor aggressiveness. miRNAs are small, noncoding 
RNA species with a length of 20–22 nucleotides that 
negatively regulate gene expression interfering with 
mRNA abundance and transcriptional efficiency [14, 15].
It is well known that in cancer, miRNAs play a 
key role in regulating the expression of genes associated 
with carcinogenesis or tumor suppression. Accordingly, 
changes in miRNAs expression levels may allow the 
identification of biological alterations, such as epithelial-
mesenchymal transition (EMT), which represent a 
crucial event in cancer progression and aggressiveness 
[16–19]. For instance, we have recently demonstrated 
the involvement of NGAL and MMP-9 in bladder cancer 
development and progression [20]. The role of these 
proteins in tumor invasion and metastatic dissemination 
is largely known as they interact with each other forming 
the NGAL/MMP-9 complex that in turn promotes the 
extracellular matrix degradation process necessary for 
tumor spreading [21, 22]. Therefore, it was intriguing 
to identify which miRNAs may be able to modulate the 
expression of such proteins in bladder cancer.
On these bases, in the present study we performed 
a computational analysis to identify which miRNAs 
were differentially expressed between bladder cancer 
patients and related healthy controls. Furthermore, among 
these miRNAs we identified which of them are able to 
interact with a wide range of genes involved in EMT and 
NGAL/MMP-9 pathways but also in many other different 
cancer pathways. The identification of these miRNAs 
may be useful for the early diagnosis of bladder cancer 
development and progression.
RESULTS
Identification of putative miRNAs of interest in 
bladder cancer
The differential analysis between bladder cancer 
patients and related healthy controls revealed 15 different 
miRNAs that were differentially expressed in both 
GSE40355 and GSE39093 datasets (p < 0.01) (Table 1). 
Among these, 9 were up-regulated and 6 were down-
regulated with similar expression levels in both datasets. 
Moreover, the differential analysis between high-grade 
and low-grade bladder cancer revealed that the hsa-miR-
18b-5p was the only miRNA differentially expressed in 
both datasets (p < 0.05) (Table 1). 
Among the 16 miRNAs described in the Table 1, 
we performed the top 10 list of the most up-regulated 
or down-regulated miRNAs for each dataset. Then, we 
merged both top 10 lists of miRNAs of the two datasets 
and identified the following six miRNAs: hsa-miR-182-5p, 
hsa-miR-200a-3p, hsa-miR-99a-5p, hsa-miR-100-5p, hsa-
miR-145-5p and hsa-miR-214-3p.
Putative miRNAs involved in epithelial to 
mesenchymal transition and NGAL/MMP-9 
pathways
Prediction analysis performed by mirDIP 
bioinformatic tool showed how the 16 selected miRNAs 
are able to target a wide range of genes involved in the 
EMT. As shown in Figure 1, several miRNAs can alter 
the expression of multiple EMT genes simultaneously, 
probably playing a major key role in cancer development 
and aggressiveness. For each miRNA was also reported the 
value of specificity against related target genes (Figure 1).
The use of mirDIP software has also allowed us to 
identify differentially expressed miRNAs that were down-
regulated in bladder cancer and therefore responsible for 
the increase of gene expression of MMP-9 and NGAL in 
cancer patients.
At first, 452 miRNAs, modulating the NGAL 
expression, were identified. Among these, the following 
miRNAs hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-
145-5p and hsa-miR-214-3p were included in the group of 
16  miRNAs listed in the Table 1 and were down-regulated 
in tumor samples when compared to healthy controls in 
both GSE40355 and GSE39093 datasets (Table 2). 
Similarly, mirDIP analysis identified 628 miRNAs 
able to recognize and degrade the MMP-9 mRNA. Among 
these, only the miRNAs hsa-miR-145-5p, hsa-miR-214-3p 
and hsa-miR-125b-5p were down regulated in tumor 
samples when compared to healthy controls in the same 
two datasets (Table 3). According to this analysis, it is 
clear that both hsa-miR-214-3p and hsa-miR-145-5p 
miRNAs may be able to target and modulate MMP-9 and 
NGAL genes. Therefore, their role in tumor cell invasion 
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and dissemination may be indicated. 
Identified miRNAs in the main pathways in 
cancer
To understand the role of miRNAs in cancer 
development, the DIANA-mirPath analysis of the six 
selected highly-modulated miRNAs in both bladder 
cancer datasets was performed. The data showed that the 
miRNAs hsa-miR-182-5p, hsa-miR-200a-3p, hsa-miR-
99a-5p, hsa-miR-100-5p, hsa-miR-145-5p, hsa-miR-
214-3p may alter the transcriptional levels of several 
genes grouped in different pathways such as bladder 
cancer pathway (has05219), adherens junction pathway 
(hsa04520), PIK3CA-Akt signal pathway (hsa04151), 
MAPK signal pathway (hsa04010) and in general cancer 
pathways (hsa05200) (Table 4).
DISCUSSION
Recently, the discovery of extracellular miRNAs, 
relatively stable in serum, plasma and urine has generated 
a considerable interest, since the variations in their 
expression levels can be used as non-invasive indicators 
for different kinds of diseases, including cancer. 
Currently, no specific markers are available for the early 
detection of bladder cancer. In this context, the analysis 
of specific miRNAs may represent a good model for the 
early diagnosis and follow-up in different cancer types, 
including bladder cancer [23–25].
A growing number of studies analyzed circulating 
miRNAs in different tumor types including those of 
bladder. However, their role in cancer development or 
progression was not deeply clarified. To our knowledge, 
this is the first computational study analyzing the putative 
miRNA interacting with oncogenic pathways involved in 
bladder cancer.
First, the analysis was conducted on non-coding 
RNA profiling by array datasets to identify putative 
miRNAs differentially expressed in bladder cancer patients 
and healthy controls. This preliminary bioinformatics 
approach allowed us to identify six different miRNAs 
involved in bladder cancer (hsa-miR-182-5p, hsa-miR-
200a-3p, hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-145-
5p and hsa-miR-214-3p). 
We recently observed that NGAL/MMP-9 complex 
plays an active role in proliferation, differentiation, 
tissue development, and tumor development of bladder 
cancer progression [21]. Of note, NGAL and MMP-9 are 
molecules that are found in the tumor microenvironment. 
Table 1: miRNAs differentially expressed in bladder cancer patients and healthy controls in both 
GSE40355 and GSE39093 datasets
 miRNAs Fold Change (GSE40355) Fold Change (GSE39093)
















High vs Low (p < 0.05)
 hsa-miR-18b-5p 17.88 0.65
* Top 10 miRNAs differentially expressed. In bold are reported the miRNAs within the top 10 of both datasets.
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Table 2: miRNAs differentially expressed in tumors compared to healthy controls able to target 
NGAL gene according microRNA Data Integration Portal (mirDIP)
 miRNAs Source Score Std Rank
Up-regulated
hsa-miR-18b-5p PITA_0_0_ALL 54.16 mid_third
hsa-miR-182-5p RNA22_v_14May2011 7.64 mid_third
hsa-miR-19b-3p RNA22_v_14May2011 0.21 bottom_third
Down-regulated
hsa-miR-145-5p RNA22_v_14May2011 19.42 top_third
hsa-miR-99a-5p RNA22_v_14May2011 16.32 top_third
hsa-miR-100-5p RNA22_v_14May2011 6.82 bottom_third
 hsa-miR-214-3p microrna_org_conserved_aug_1020 2.59 bottom_third
Figure 1: miRNAs able to target the most important genes involved in the ephythelial-mesenchymal transition. The 
gradations of color correspond to the specific values of each miRNA to the target genes. SNAI1: snail family zinc finger 1; SNAI2: snail 
family zinc finger 2; TWIST1: twist bHLH family transcription factor 1; TWIST2: twist bHLH family transcription factor 2; CDH1: 
E-cadherin; CTNNB1: β-catenin; ZEB1: zinc finger E-box binding homeobox 1; ZEB2: zinc finger E-box binding homeobox 2; VIM: 
vimentin.
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In particular, NGAL regulates the expression of MMP-9, 
which is responsible for several physiological and 
pathological processes including the enzymatic remodeling 
of the extracellular matrix during angiogenesis, tumor 
growth and metastasis. These two proteins form the 
MMP-9/NGAL complex capable of protecting MMP-9 
from proteolytic degradation and hence favoring the 
tumor invasiveness. These mechanisms are supported 
by our previous computational analysis, performed by 
“The Human Protein Atlas” (http://www.proteinatlas.
org/), which suggested an active role of NGAL, in 
cancer development in different tumor histotypes [26]. 
Accordingly, the result of the present study show that 
the down-regulated hsa-miR-145-5p and hsa-miR-214-
3p are able to modulate MMP-9 and NGAL genes and 
also some genes of EMT pathway. In particular, the 
epigenetic modification of EMT pathway made by the 
miRNAs may represent a fundamental step in malignance 
transformation of tumor cells. Several studies support the 
idea that miRNAs are strictly involved in the regulation 
of epithelial-to-mesenchymal transition in which tumor 
cells tumor cells acquire new mesenchymal characteristics 
and lose their original epithelial features [27, 28]. The 
results of this transformation are the increase of tumor 
aggressiveness, of metastatic lesions and the development 
of resistance to chemo- immunotherapies [29, 30].
In addition, DIANA-mirPath analysis has shown that 
the six selected miRNAs have a fundamental role in different 
cancer pathways highlighting their possible involvement in 
bladder cancer. The bioinformatics tool revealed that the 
miRNAs identified are able to target several genes, such as 
FGFR3, MTOR, FOXO1, MYC, TP53, STAT1 etc., known 
to be involved in cancer onset and development [31–35]. 
The modulation of these cancer pathways and genes by 
the miRNA induces the increase of cell proliferation and 
inhibition of tumor cell apoptosis leading to tumor spreading.
Furthermore, the detection of these putative 
miRNAs for the early diagnosis of cancer can be very 
effective in bladder because the analysis can be extended 
not only in serum or plasma samples, but also in urine 
samples where these miRNAs may be directly released by 
tumor cells, even in the early stages of the disease [36, 37].
Further studies will be needed to determine the 
levels of sensitivity and specificity of the putative 
miRNAs identified in this study in predicting the 
development of bladder cancer. In particular, the analysis 
will be conducted on a wide range of patients with bladder 
cancer and related healthy controls. The analysis will be 
conducted to determine the expression levels of hsa-miR-
145-5p and hsa-miR-214-3p, able to modulate MMP-9 
and NGAL expression levels. In addition, the analysis of 
hsa-miR-182-5p, hsa-miR-200a-3p, hsa-miR-99a-5p, hsa-
miR-100-5p will be performed because these miRNAs 
were found to be the most differentially expressed between 
bladder cancer patients and related healthy controls in both 
GSE40355 and GSE39093 datasets.
Table 3: miRNAs differentially expressed in tumors compared to healthy controls able to target 
MMP-9 gene according microRNA Data Integration Portal (mirDIP)
miRNAs Source Score Std Rank
Up-regulated
hsa-miR-200a PITA_0_0_ALL 47.67 bottom_third
hsa-miR-141 PITA_0_0_ALL 46.38 bottom_third
hsa-miR-130b RNA22_v_14May2011 17.98 top_third
hsa-miR-138 RNA22_v_14May2011 16.32 top_third
hsa-miR-934 RNA22_v_14May2011 15.29 top_third
hsa-miR-7 RNA22_v_14May2011 14.05 mid_third
hsa-miR-513b RNA22_v_14May2011 11.36 mid_third
hsa-miR-16 RNA22_v_14May2011 10.12 mid_third
hsa-miR-200a RNA22_v_14May2011 7.23 bottom_third
hsa-miR-106b RNA22_v_14May2011 6.40 bottom_third
hsa-miR-182 RNA22_v_14May2011 5.99 bottom_third
hsa-miR-141 RNA22_v_14May2011 3.72 bottom_third
Down-regulated
hsa-miR-145 RNA22_v_14May2011 22.11 top_third
hsa-miR-214 RNA22_v_14May2011 21.28 top_third
hsa-miR-195 RNA22_v_14May2011 13.22 mid_third
hsa-miR-125b RNA22_v_14May2011 7.23 bottom_third
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Finally, the study on specific miRNAs differentially 
expressed in bladder cancer patients could have a great 
clinical implication because miRNAs are detectable not 
only in tissue samples but also in several biological fluids, 
such as in plasma and urine, where circulating tumor 
cells (CTCs) release them. According to these hypothesis, 
the identification of changes in the expression levels of 
individual or multiple miRNAs directly into peripheral 
blood, or in urine, may represent a new strategy for the 
early detection of cancer and for the prediction of cancer 
recurrence development [38–41]. 
MATERIALS AND METHODS
miRNAs computational analysis
In order to identify putative miRNAs that were 
differentially expressed between bladder cancer patients 
and related healthy controls, datasets of non-coding RNA 
profiling available on Gene Expression Omnibus (GEO) 
Dataset (www.ncbi.nlm.nih.gov/geo/) were analyzed. 
Among all publicly available GEO datasets, only 
those containing bladder cancer samples with miRNAs 
expression levels, clinical data and relative normal 
controls were analyzed. According to these criteria only 
the datasets GSE40355 and GSE39093 were used for our 
analysis [42, 43]. 
The GSE40355 dataset (Agilent-019118 Human 
miRNA Microarray 2.0 G4470B [miRNA ID version]) 
includes 8 samples of high-grade papillary urothelial 
carcinoma, 8 low-grade papillary urothelial carcinoma and 
8 samples of nonmalignant bladder. For all 24 samples 
clinical data were available. The GSE39093 dataset 
([miRNA-1_0] Affymetrix miRNA Array) includes 
5 samples of non-muscle invasive bladder cancer 
(NMIBC) and 5 corresponding adjacent normal tissue, and 
5 samples of muscle invasive bladder cancer (MIBC) and 
5 corresponding adjacent normal tissue. For all 20 samples 
clinical data were available.
Differential analysis of miRNAs expression levels 
(fold change value) between tumor and normal samples 
was performed in both datasets. Furthermore, the 
differential analysis between high-grade and low-grade 
bladder cancer was performed in the same manner.
Finally was performed the top 10 list of the most 
up-regulated or down-regulated miRNAs for each dataset. 
This analysis allowed us to identify the 10 most up-
regulated and down-regulated miRNAs in bladder cancer 
compared to healthy controls. Subsequently, among these, 
were selected the 6 miRNAs in common and strongly 
modulated in both datasets.
Table 4: Interaction between selected miRNAs and target genes in different pathways (DIANA-
mirPath v.2)
miRNAs p Value Gene Target
Pathways in cancer (hsa05200)
hsa-miR-200a-3p 0.006320485 TCF7L1, CTNNB1
hsa-miR-182-5p 0.01027914 MITF, EP300, CDKN1A, FOXO1
hsa-miR-99a-5p 0.006069299 FGFR3, MTOR
hsa-miR-145-5p 0.000288274 IGF1R, TPM3, MMP1, MYC, CDKN1A, STAT1




hsa-miR-145-5p 0.000288274 MMP1, MYC, CDKN1A
hsa-miR-214-3p 0.00565335 TP53, DAPK1
Adherens junction (hsa04520)
hsa-miR-200a-3p 1.30E–06 TCF7L1, WASF3, CTNNB1
PI3K-Akt signaling pathway (hsa04151)
hsa-miR-99a-5p 0.005785765 FGFR3, MTOR
hsa-miR-100-5p 0.04890642 FGFR3
MAPK signaling pathway (hsa04010)
hsa-miR-100-5p 0.03917171 FGFR3
hsa-miR-214-3p 0.002472282 MAP2K5, MAP2K3, TP53, RASA1, MAPK8
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Interaction between selected miRNAs and 
epithelial-mesenchimal transition pathway
Through the use of the bioinformatic prediction 
tool microRNA Data Integration Portal (mirDIP) 
(http://ophid.utoronto.ca/mirDIP), was evaluated the 
interaction between the miRNA previously identified 
by computational analysis and the main genes involved 
in EMT [44]. This bioinformatics software integrates 
twelve microRNA prediction datasets from six different 
microRNA prediction databases providing a list of EMT 
gene targeting the specific miRNAs previously indentified.
These genes are SNAI1: snail family zinc finger 1; 
SNAI2: snail family zinc finger 2; TWIST1: twist family 
bHLH transcription factor 1; TWIST2: twist family bHLH 
transcription factor 2; CDH1: E-caderina; CTNNB1: 
β-catenina; ZEB1: zinc finger E-box binding homeobox 1; 
ZEB2: zinc finger E-box binding homeobox 2; VIM: 
vimentina.
Subsequently we used the mirDIP software to predict 
which selected miRNAs are able to target the MMP-9 and 
NGAL genes of which our research group is already in 
possession of serum and urine expression levels [20].
Interaction between selected miRNAs and main 
pathways in cancer
miRNAs are not only involved in the epithelial-
mesenchymal transition, but are able to interact with a 
wide range of genes involved in different cancer pathways. 
Through the use of the bioinformatic tool DIANA-
mirPath (v.2) the top ten differentially expressed miRNA 
were analyzed to predict miRNA targets in 3′-UTR 
gene regions according to experimentally validated 
miRNA interactions derived from DIANA-TarBase v6.0 
algorithm. These interactions (predicted and/or validated) 
were subsequently combined with sophisticated merging 
and meta-analysis algorithms by DIANA-mirPath.
Statistical analysis
Statistical analyses and Student’s t-Tests were 
performed to select the differentially expressed miRNAs 
as previously described [45]. No additional normalization 
procedures were applied to data obtained from GSE40355 
and GSE39093 datasets included in this study.
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